id: NEW:colistin_meropenem_combination_therapy_to_NEW:nosocomial_pneumonia_clinical_improvement
name: Colistin Plus Meropenem Combination Therapy â†’ Nosocomial Pneumonia Clinical
  Improvement
from_node:
  node_id: NEW:colistin_meropenem_combination_therapy
  node_name: Colistin Plus Meropenem Combination Therapy
to_node:
  node_id: NEW:nosocomial_pneumonia_clinical_improvement
  node_name: Nosocomial Pneumonia Clinical Improvement
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Colistin disrupts the outer membrane of multidrug-resistant gram-negative
  bacteria by binding to lipopolysaccharides, increasing bacterial cell permeability'
- 'Step 2: Meropenem, a carbapenem antibiotic, inhibits bacterial cell wall synthesis
  by binding to penicillin-binding proteins, providing broad-spectrum bactericidal
  activity'
- 'Step 3: The combination therapy produces synergistic antimicrobial effects against
  resistant pathogens causing nosocomial pneumonia, with colistin facilitating meropenem
  entry into bacterial cells'
- 'Step 4: Enhanced bacterial eradication leads to reduced inflammatory response,
  decreased organ dysfunction (lower SOFA scores), and improved clinical outcomes
  in hospitalized patients'
evidence:
  quality_rating: B
  n_studies: 5
  primary_citation: Hazhir Moradi et al. 2024. Systematic review and meta-analysis
    of colistin plus meropenem therapy for the treatment of nosocomial pneumonia.
    Iranian journal of microbiology.
  supporting_citations: []
description: Colistin plus meropenem combination therapy significantly improves clinical
  outcomes in patients with nosocomial pneumonia caused by multidrug-resistant gram-negative
  bacteria. The meta-analysis of 5 studies with 991 patients demonstrated that this
  combination therapy is superior to other colistin-based treatments, with an odds
  ratio of 1.37 for clinical improvement. The therapy also significantly reduced Sequential
  Organ Failure Assessment scores, indicating improved organ function.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 1.37
    type: odds_ratio
    ci_lower: 1.04
    ci_upper: 1.81
  p_value: 0.027
  sample_size: 991
moderators:
- name: Baseline organ dysfunction (SOFA score)
  direction: strengthens
  strength: moderate
  description: Patients with higher baseline organ dysfunction may benefit more from
    combination therapy, as evidenced by significant SOFA score reduction (OR = -0.28,
    p = 0.001)
- name: Comorbidity burden (Charlson Comorbidity Index)
  direction: strengthens
  strength: weak
  description: Combination therapy showed increased CCI scores (OR = 0.16, p = 0.021),
    suggesting potential differential effects based on comorbidity burden
